HMPL-813 in Treating Patients With Glioblastoma

Phase 1

• Conditions: Glioblastoma
• Interventions: Drug: epitinib succinate

• Registration Number: NCT03231501
• Lead Sponsor: Hutchison Medipharma Limited

Brief Summary

This is an open-label study, to evaluated epitinib, which is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), to treat glioblastoma patients with EGFR gene amplification. As epitinib could cross blood-brain barrier (BBB), inhibition of EGFR may provide a novel mechanism in treating glioblastoma.

Detailed Description

Epitinib could cross BBB and show its efficacy in brain metastasis tumors. Patients with histologically confirmed glioblastoma; standard treatment failed or no standard treatment as well as EGFR gene amplication are eligible. Patients will receive epitinib 120mg or 160mg epitinib daily. Epitinib is orally administered qd until patients reach intolerance or progression of disease. Tumor assessment takes place every 4 weeks. Simon two stage design was used, estimated making sample size of 35 cases.

Study Timeline

• Study First Submitted: 2017-07-19
• Study First Submitted QC: 2017-07-24
• Study First Posted: 2017-07-27
• Study Start: 2018-01-26
• Status Verified: 2020-06
• Last Update Submitted: 2020-06-12
• Last Update Posted: 2020-06-16
• Primary Completion: 2020-06-30
• Study Completion: 2020-08-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

1. Histologically confirmed glioblastoma
2. Standard treatment failed or no standard treatment
3. EGFR gene amplification
4. Clearly measurable lesions (according to Response Assessment in Neuro-Oncolog (RANO))
5. Age ≥ 18
6. Eastern Cooperative Oncology Group (ECOG) score ≤2

Exclusion Criteria

1. Use of Antiepileptic drugs were used] within 2 weeks before enrollment
2. Immunotherapy, anti-angiogenesis or EGFR TKI and its downstream pathway signaling molecules and other targeted drugs within 4 weeks before enrollment; temozolomide chemotherapy, cranial radiotherapy or other systemic anti-tumor therapy within 3 weeks before enrollment
3. Previous toxic effects of anticancer therapy have not yet been recovered (defined as not restored to 0 or 1 level, except alopecia) or have not been fully recovered from previous surgery
4. Uncontrolled active infections such as acute pneumonia, Hepatitis B Virus (HBV) and so on
5. Eye disease or dry eye syndrome history
6. Positive pregnancy tested result

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
single arm	epitinib succinate	This is a single arm study. It is an open-label study. The intervention is eptinib succinate.

Primary Outcome Measures

Name	Time	Method
objective response rate (ORR)	6 months	the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period

Trial Locations

Locations (2)

The second hospital affiliated to Zhejiang University Medical School; 🇨🇳 Hanzhou, Zhejiang, China

Huashan Hospital; 🇨🇳 Shanghai, Shanghai, China